Real-World Experience of Treating Young Adult Patients with Breast Cancer from a Single Center in Southern India

Abstract

Priya Iyer

Background Breast cancer in young adults is rare and accounts for 5 to 6% of all cancers in this age group. We conducted the present study to look at the demographic features, clinical presentation, and outcomes in this group of patients treated at our center.

Patients and Methods The study included breast cancer patients between the age of 15 and 30 years treated at our institute from January 2009 to December 2016. Data were analyzed retrospectively from case records. Event-free survival (EFS) and overall survival (OS) were calculated using the Kaplan–Meier method.

Results Young adult breast cancers were reported in 145 out of 6,000 patients (2.41%) diagnosed with breast cancer in the study period. The median age of the patients was 29 years (range: 21–30 years). Stage I, II, III, and IV was observed in 3.4, 33.7, 46.2, and 16.5% of patients, respectively. The median follow-up was 45 months (range: 1.7–128.1 months). The 5-year EFS and OS for stage I, II, III, and IV was 100, 74.5, 47.9, and 0% and 100, 90.8, 55.1, and 0%, respectively. On univariate analysis, stage of the disease and pregnancy-associated breast cancers were found to have a significant association with decreased EFS and OS (p < 0.001, p = 0.008 and p < 0.001, p = 0.001, respectively). On multivariate analysis, stage of disease and pregnancy-associated breast cancers remained significant predictors of EFS and OS.

Conclusion Breast cancers in young adults are rare but need to be diagnosed at an early stage to improve survival. Pregnancy-associated breast cancers need to be managed optimally without delay owing to their aggressive tumor biology.

Keywords

breast cancer - survival - chemotherapy

Study Design and Ethics

Retrospective analysis of patient case records do not require formal ethics approval at our institute. The study was conducted according to the criteria set by the Declaration of Helsinki. Written informed consent was obtained from all patients before starting the planned treatment.

Publication History

Article published online:
10 February 2022

• References

• 1 Rojas K, Stuckey A. Breast cancer epidemiology and risk factors. Clin Obstet Gynecol 2016; 59 (04) 651-672
• 2 Vishwakarma G, Ndetan H, Das DN. et al. Reproductive factors and breast cancer risk: a meta-analysis of case-control studies in Indian women. South Asian J Cancer 2019; 8 (02) 80-84
• 3 Radecka B, Litwiniuk M. Breast cancer in young women. Ginekol Pol 2016; 87 (09) 659-663
• 4 Arnould L, Penault-Llorca F, Dohollou N, Caron O, Levy C. Cancer du sein de la femme jeune. Spécificités histologiques, pronostiques : en quoi sont-elles différentes des femmes plus âgées? [Breast cancer in young women. Histological and prognostic specificities: how are they different from older women?]. Bull Cancer 2019; 106 (12S1): S10-S18
• 5 Hironaka-Mitsuhashi A, Tsuda H, Yoshida M. et al. Invasive breast cancers in adolescent and young adult women show more aggressive immunohistochemical and clinical features than those in women aged 40-44 years. Breast Cancer 2019; 26 (03) 386-396
• 6 Ribnikar D, Ribeiro JM, Pinto D. et al. Breast cancer under age 40: a different approach. Curr Treat Options Oncol 2015; 16 (04) 16
• 7 Johnson RH, Anders CK, Litton JK, Ruddy KJ, Bleyer A. Breast cancer in adolescents and young adults. Pediatr Blood Cancer 2018; 65 (12) e27397
• 8 Laurence V, Marples M, Stark DP. Adult cancers in adolescents and young adults. Prog Tumor Res 2016; 43: 64-73
• 9 Christian N, Gemignani ML. Issues with fertility in young women with breast cancer. Curr Oncol Rep 2019; 21 (07) 58
• 10 Sharma D, Singh G. Breast cancer in young women: a retrospective study from tertiary care center of North India. South Asian J Cancer 2017; 6 (02) 51-53
• 11 Gogia A, Raina V, Deo SV, Shukla NK, Mohanti BK. Young breast cancer: a single center experience. Indian J Cancer 2014; 51 (04) 604-608
• 12 Iyer P, Radhakrishnan V, Balasubramanian A. et al. Study of pathological complete response rate with neoadjuvant concurrent chemoradiation with paclitaxel in locally advanced breast cancer. Indian J Cancer 2020; 57 (04) 428-434
• 13 Bae SY, Kim KS, Kim JS. et al; Korean Breast Cancer Society. Neoadjuvant chemotherapy and prognosis of pregnancy-associated breast cancer: a time-trends study of the Korean Breast Cancer Registry Database. J Breast Cancer 2018; 21 (04) 425-432
• 14 Melvin JC, Wulaningsih W, Hana Z. et al. Family history of breast cancer and its association with disease severity and mortality. Cancer Med 2016; 5 (05) 942-949
• 15 Yao Y, Cao M, Fang H, Xie J. Breast cancer in 30-year-old or younger patients: clinicopathologic characteristics and prognosis. World J Surg Oncol 2015; 13: 38
• 16 Blackwell K, Gligorov J, Jacobs I, Twelves C. The global need for a trastuzumab biosimilar for patients with HER2-positive breast cancer. Clin Breast Cancer 2018; 18 (02) 95-113
• 17 Azim Jr HA, Partridge AH. Biology of breast cancer in young women. Breast Cancer Res 2014; 16 (04) 427
• 18 Krishna I, Lindsay M. Breast cancer in pregnancy. Obstet Gynecol Clin North Am 2013; 40 (03) 559-571
• 19 Genin AS, Lesieur B, Gligorov J, Antoine M, Selleret L, Rouzier R. Pregnancy-associated breast cancers: do they differ from other breast cancers in young women?. Breast 2012; 21 (04) 550-555
• 20 Freedman RA, Partridge AH. Management of breast cancer in very young women. Breast 2013; 22 (Suppl. 02) S176-S179
• 21 Gerstl B, Sullivan E, Ives A, Saunders C, Wand H, Anazodo A. Pregnancy outcomes after a breast cancer diagnosis: a systematic review and meta-analysis. Clin Breast Cancer 2018; 18 (01) e79-e88